Calidi Biotherapeutics (CLDI) Retained Earnings (2022 - 2026)
Calidi Biotherapeutics (CLDI) posted quarterly Retained Earnings of $145.4 million for Q4 2025, up 17.94% year-over-year from $123.3 million in Q4 2024, and up 1118500.0% quarter-over-quarter from -$13000.0 in Q3 2025.
Calidi Biotherapeutics (CLDI) Retained Earnings (2022 - 2026) Analysis & Trends
Calidi Biotherapeutics' Retained Earnings history runs 4 years deep, the most recent figure standing at $145.4 million for Q4 2025.
- In Q4 2025, Retained Earnings rose 17.94% year-over-year to $145.4 million; the TTM figure through Dec 2025 stood at $145.4 million (up 17.94% YoY), while the FY2025 annual figure was $145.4 million, up 17.94% from the prior year.
- Retained Earnings for Q4 2025 stood at $145.4 million, up from -$13000.0 in the prior quarter.
- The five-year high for Retained Earnings was $145.4 million in Q4 2025, with the low at -$112.6 million in Q2 2024.
- The 4-year median for Retained Earnings is -$4.7 million (2022), against an average of -$10.3 million.
- Peak annual rise in Retained Earnings reached 262391.49% in 2024, while the deepest fall reached 826.53% in 2024.
- Calidi Biotherapeutics' Retained Earnings stood at -$70.4 million in 2022, then surged by 99.93% to -$47000.0 in 2023, then surged by 262391.49% to $123.3 million in 2024, then increased by 17.94% to $145.4 million in 2025.
- Business Quant data shows CLDI's Retained Earnings at $145.4 million in Q4 2025, -$13000.0 in Q3 2025, and -$13000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Calidi Biotherapeutics | 1.88 Mn | -2.22 Mn | - | 153.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 153.05 Mn |
| Dec 31, 2025 | 145.39 Mn |
| Sep 30, 2025 | -13,000.00 |
| Jun 30, 2025 | -13,000.00 |
| Mar 31, 2025 | -26,000.00 |
| Dec 31, 2024 | 123.28 Mn |
| Sep 30, 2024 | -74,000.00 |
| Jun 30, 2024 | -112.60 Mn |
| Mar 31, 2024 | -106.80 Mn |
| Dec 31, 2023 | -47,000.00 |
| Sep 30, 2023 | -91.34 Mn |
| Jun 30, 2023 | -12.15 Mn |
| Dec 31, 2022 | -70.36 Mn |
| Sep 30, 2022 | -9.90 Mn |
| Jun 30, 2022 | -9.24 Mn |